BUDGET IMPACT ANALYSIS OF APREMILAST ON MODERATE TO SEVERE PSORIASIS IN SPAIN

被引：0
|
作者：
Vanaclocha, F. [1 ]
Carrascosa, J. M. [2 ]
Caloto, T. [3 ]
Elias, I [4 ]
Echave, M. [4 ]
Tencer, T. [5 ]
机构：
[1] 12 Octubre Univ Hosp, Dept Dermatol, Madrid, Spain
[2] Germans Trias & Pujol Univ Hosp, Dept Dermatol, Barcelona, Spain
[3] Celgene Corp, Dept Econ, Madrid, Spain
[4] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[5] Celgene Corp, Warren, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.559
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS35
引用
收藏
页码：A421 / A421
页数：1
相关论文
共 50 条
  • [41] Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis
    Sacchelli, L.
    Patrizi, A.
    Loi, C.
    Bardazzi, F.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2019, 44 (07) : E243 - E244
  • [42] Apremilast With Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis
    Bagel, Jerry
    Nelson, Elise
    Riley, Cheryl
    Hetzel, Alexa
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (12) : 1149 - 1155
  • [43] Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: A systematic review and meta-analysis
    Aljefri, Yara E.
    Ghaddaf, Abdullah A.
    Alkhunani, Tala A.
    Alkhamisi, Taif A.
    Alahmadi, Rana A.
    Alamri, Awadh M.
    Alraddadi, Ali A.
    DERMATOLOGIC THERAPY, 2022, 35 (07)
  • [44] Comparison of risankizumab with apremilast for the treatment of moderate psoriasis
    不详
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (05) : E85 - E85
  • [45] BUDGET IMPACT OF SECUKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS IN MEXICO
    Tierrablanca, L.
    Botello, B. S.
    Gomar, D.
    Ubiarco, V
    VALUE IN HEALTH, 2019, 22 : S252 - S252
  • [46] THE BUDGET IMPACT OF BRODALUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS ON US COMMERCIAL HEALTH PLANS
    Feldman, S. R.
    Wu, J. J.
    Rastogi, S.
    Menges, B.
    Lingohr-Smith, M.
    Lin, J.
    VALUE IN HEALTH, 2018, 21 : S239 - S240
  • [47] DIMETHYL FUMARATE FOR THE TREATMENT OF FIRST-LINE MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ITALY: A BUDGET-IMPACT ANALYSIS
    Galimi, M. A.
    Pi, A.
    Belisari, A.
    Prades, M.
    VALUE IN HEALTH, 2020, 23 : S524 - S524
  • [48] The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans
    Feldman, Steven R.
    Wu, Jashin J.
    Rastogi, Shipra
    Menges, Brandy
    Lingohr-Smith, Melissa
    Lin, Jay
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (05) : 537 - 541
  • [49] Circulating Monocytes Are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subject Treated with Apremilast
    Larson, Emma L.
    DeMeo, Dustin P.
    Young, Andrew B.
    Margevicius, Seunghee
    Rutter, Joseph
    Davies, Amanda L.
    Rohan, Craig A.
    Korman, Neil J.
    Travers, Jeffrey B.
    McCormick, Thomas S.
    Cooper, Kevin D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (09) : 1963 - 1974.e13
  • [50] Cost per responder of apremilast versus etanercept, adalimumab, and ustekinumab in patients with moderate to severe psoriasis
    Feldman, Steven R.
    Tencer, Tom
    Clancy, Zoe
    Zhang, Frank
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB229 - AB229
12345